» Articles » PMID: 30275410

Association of Uremic Toxins and Inflammatory Markers with Physical Performance in Dialysis Patients

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2018 Oct 3
PMID 30275410
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Association of higher serum levels of uremic toxins and inflammatory markers with poorer physical performance is understudied. We measured the six-minute walk test (6MWT), 10 repetition sit-to-stand test (STS-10), handgrip strength (HGS), and Human Activity Profile (HAP) questionnaire score in 90 prevalent hemodialysis patents, with low comorbidity to reduce the potential confounding of concomitant disease. Midweek pre-dialysis serum levels of asymmetric dimethyl-arginine (ADMA), β2-microglobulin (B2M), high-sensitivity C-reactive protein (hs-CRP), indoxyl sulfate (IS), insulin-like growth factor 1 (IGF-1), interleukin 6 (IL-6), myostatin, and urea were analyzed as predictor parameters of physical performance measures in adjusted models. Serum levels of most measured toxins were not significantly related to performance, except for ADMA, which was significantly related to poorer performance in the STS-10 test (B = 0.11 ± 0.03 s, < 0.01). Higher hs-CRP was associated with poorer results in the 6MWT (B = -2.6 ± 0.97 m, < 0.01) and a lower HAP score (B = -0.36 ± 0.14, = 0.01). There were no other significant associations found. We conclude that inflammation may be a more important pathway to physical impediment than uremic toxemia. This suggests that there is a large physical rehabilitation potential in non-inflamed uremic patients.

Citing Articles

The prevalence of frailty according to kidney function and its association with cognitive impairment, nutritional status, and clinical outcome.

Yang T, Kang Y, Kim D, Kim Y, Kwon O, Lee T BMC Nephrol. 2025; 26(1):65.

PMID: 39930363 PMC: 11808967. DOI: 10.1186/s12882-025-04006-5.


Prevalence of Impaired Physical Mobility in Dialysis Patients: A Single-Centre Cross-Sectional Study.

Bogataj S, Pajek J, Slonjsak B, Persic V J Clin Med. 2023; 12(20).

PMID: 37892773 PMC: 10607894. DOI: 10.3390/jcm12206634.


Association between asymmetric dimethylarginine and sarcopenia in community-dwelling older women.

Yokoro M, Otaki N, Yano M, Imamura T, Tanino N, Fukuo K Sci Rep. 2023; 13(1):5510.

PMID: 37015998 PMC: 10073180. DOI: 10.1038/s41598-023-32046-0.


Association of endothelial dysfunction with sarcopenia and muscle function in a relatively young cohort of kidney transplant recipients.

Khoo S, Lin Y, Ho G, Lee M, Hsu B PeerJ. 2021; 9:e12521.

PMID: 34900434 PMC: 8614188. DOI: 10.7717/peerj.12521.


Uremic Toxins and Frailty in Patients with Chronic Kidney Disease: A Molecular Insight.

Chao C, Lin S Int J Mol Sci. 2021; 22(12).

PMID: 34200937 PMC: 8230495. DOI: 10.3390/ijms22126270.


References
1.
Obayashi K, Saeki K, Maegawa T, Sakai T, Kitagawa M, Otaki N . Association of Serum Asymmetric Dimethylarginine With Muscle Strength and Gait Speed: A Cross-Sectional Study of the HEIJO-KYO Cohort. J Bone Miner Res. 2015; 31(5):1107-13. DOI: 10.1002/jbmr.2773. View

2.
Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G . An update on uremic toxins. Int Urol Nephrol. 2012; 45(1):139-50. DOI: 10.1007/s11255-012-0258-1. View

3.
Buckley D, Fu R, Freeman M, Rogers K, Helfand M . C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(7):483-95. DOI: 10.7326/0003-4819-151-7-200910060-00009. View

4.
Carrero J, Stenvinkel P, Cuppari L, Ikizler T, Kalantar-Zadeh K, Kaysen G . Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013; 23(2):77-90. DOI: 10.1053/j.jrn.2013.01.001. View

5.
Bucar Pajek M, Cuk I, Leskosek B, Mlinsek G, Ponikvar J, Pajek J . Six-Minute Walk Test in Renal Failure Patients: Representative Results, Performance Analysis and Perceived Dyspnea Predictors. PLoS One. 2016; 11(3):e0150414. PMC: 4794199. DOI: 10.1371/journal.pone.0150414. View